tetano
Editor, Senior Moderator
J Chin Med Assoc
. 2020 Jun 15.
doi: 10.1097/JCMA.0000000000000375. Online ahead of print.
Pharmacological Development of the Potential Adjuvant Therapeutic Agents Against Coronavirus Disease 2019
Kuan-Hsuan Chen[SUP] 1 2 [/SUP], Sheng-Fan Wang[SUP] 1 2 3 [/SUP], Szu-Yu Wang[SUP] 1 [/SUP], Yi-Ping Yang[SUP] 4 5 [/SUP], Mong-Lien Wang[SUP] 3 4 [/SUP], Sih-Hwa Chiou[SUP] 4 5 [/SUP], Yuh-Lih Chang[SUP] 1 2 5 [/SUP]
Affiliations
Abstract
As the coronavirus disease 2019 (COVID-19, also called severe acute respiratory syndrome coronavirus-2, SARSCoV-2) outbreak accelerates, vigorous and diverse efforts were made in developing treatment strategies. In addition to direct acting agents, increasing evidence showed some potential adjuvant therapies with promising efficacy against COVID-19. These therapies include immunomodulators (i.e. intravenous immunoglobulin, thymosin α-1, IL-6, tocilizumab, cyclosporine, thalidomide, fingolimod), Chinese medicines (i.e. glycyrrhizin, baicalin, Xuebijing), anti-vascular endothelial growth factors (bevacizumab), estrogen modulating drugs, statins and nutritional supplements (i.e. vitamin A, B, C, D, E and zinc). This article reviewed the pharmacological development of potential adjuvants for COVID-19 treatment.
. 2020 Jun 15.
doi: 10.1097/JCMA.0000000000000375. Online ahead of print.
Pharmacological Development of the Potential Adjuvant Therapeutic Agents Against Coronavirus Disease 2019
Kuan-Hsuan Chen[SUP] 1 2 [/SUP], Sheng-Fan Wang[SUP] 1 2 3 [/SUP], Szu-Yu Wang[SUP] 1 [/SUP], Yi-Ping Yang[SUP] 4 5 [/SUP], Mong-Lien Wang[SUP] 3 4 [/SUP], Sih-Hwa Chiou[SUP] 4 5 [/SUP], Yuh-Lih Chang[SUP] 1 2 5 [/SUP]
Affiliations
- PMID: 32568969
- DOI: 10.1097/JCMA.0000000000000375
Abstract
As the coronavirus disease 2019 (COVID-19, also called severe acute respiratory syndrome coronavirus-2, SARSCoV-2) outbreak accelerates, vigorous and diverse efforts were made in developing treatment strategies. In addition to direct acting agents, increasing evidence showed some potential adjuvant therapies with promising efficacy against COVID-19. These therapies include immunomodulators (i.e. intravenous immunoglobulin, thymosin α-1, IL-6, tocilizumab, cyclosporine, thalidomide, fingolimod), Chinese medicines (i.e. glycyrrhizin, baicalin, Xuebijing), anti-vascular endothelial growth factors (bevacizumab), estrogen modulating drugs, statins and nutritional supplements (i.e. vitamin A, B, C, D, E and zinc). This article reviewed the pharmacological development of potential adjuvants for COVID-19 treatment.